AC
Armistice Capital Portfolio holdings
AUM
$2.64B
This Quarter Return
+3.4%
1 Year Return
+0.99%
3 Year Return
+16.29%
5 Year Return
+18.04%
10 Year Return
+34.8%
AUM
$3.51B
AUM Growth
+$3.51B
(-15%)
Cap. Flow
-$436M
Cap. Flow
% of AUM
-12.4%
Top 10 Holdings %
Top 10 Hldgs %
30.68%
Holding
202
New
57
Increased
36
Reduced
24
Closed
61
Top Buys
| 1 |
Home Depot
HD
|
$105M |
| 2 |
PTC Therapeutics
PTCT
|
$79.1M |
| 3 |
Target
TGT
|
$68.3M |
| 4 |
Viatris
VTRS
|
$63.1M |
| 5 |
Neurocrine Biosciences
NBIX
|
$60.9M |
Top Sells
| 1 |
Bristol-Myers Squibb
BMY
|
$67.8M |
| 2 |
Academy Sports + Outdoors
ASO
|
$66.3M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$65.8M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
$63.2M |
| 5 |
Ulta Beauty
ULTA
|
$62.1M |
Sector Composition
| 1 | Healthcare | 66.72% |
| 2 | Consumer Staples | 13.57% |
| 3 | Consumer Discretionary | 10.09% |
| 4 | Technology | 5.16% |
| 5 | Communication Services | 2.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Travere Therapeutics
TVTX
$1.56B
| $128M | 2.47% | 4,958,000 +880,000 | +22% | +$22.7M |
|
2
Incyte
INCY
$16.5B
| $121M | 2.34% | 1,524,000 -632,000 | -29% | -$50.2M |
|
3
Biogen
BIIB
$19.4B
| $120M | 2.33% | 572,000 +112,000 | +24% | +$23.6M |
|
|
4
PTC Therapeutics
PTCT
$3.92B
| $113M | 2.19% | 3,036,000 +2,118,893 | +231% | +$79.1M |
|
|
MRTX
5
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $112M | 2.17% | 1,364,000 +528,000 | +63% | +$43.4M |
|
|
6
Home Depot
HD
$405B
| $105M | 2.03% | +349,897 | New | +$105M |
|
|
7
Bristol-Myers Squibb
BMY
$96B
| $102M | 1.97% | 1,396,000 -928,000 | -40% | -$67.8M |
|
8
Supernus Pharmaceuticals
SUPN
$2.53B
| $100M | 1.94% | 3,100,000 -1,036,000 | -25% | -$33.5M |
|
9
Madrigal Pharmaceuticals
MDGL
$9.76B
| $96M | 1.86% | 978,000 -146,000 | -13% | -$14.3M |
|
10
Enanta Pharmaceuticals
ENTA
$180M
| $80M | 1.55% | 1,124,000 +68,000 | +6% | +$4.84M |
|
|
11
Jazz Pharmaceuticals
JAZZ
$7.75B
| $73.5M | 1.42% | 472,000 -406,000 | -46% | -$63.2M |
|
12
Catalyst Pharmaceutical
CPRX
$2.52B
| $69.4M | 1.34% | 8,372,000 -1,200,000 | -13% | -$9.95M |
|
|
13
Target
TGT
$43.6B
| $68.3M | 1.32% | +321,698 | New | +$68.3M |
|
14
CRISPR Therapeutics
CRSP
$4.71B
| $64.3M | 1.24% | 1,024,000 +132,000 | +15% | +$8.29M |
|
|
15
Viatris
VTRS
$12.3B
| $63.1M | 1.22% | +5,800,000 | New | +$63.1M |
|
16
argenx
ARGX
$43.6B
| $63.1M | 1.22% | 200,000 +12,000 | +6% | +$3.78M |
|
17
Central Garden & Pet Class A
CENTA
$2.08B
| $62.6M | 1.21% | 1,536,000 +468,000 | +44% | +$19.1M |
|
18
Illumina
ILMN
$15.8B
| $62.2M | 1.2% | 178,000 +63,000 | +55% | +$22M |
|
|
BHVN
19
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $62.1M | 1.2% | 524,000 +56,000 | +12% | +$6.64M |
|
|
OCDX
20
DELISTED
Ortho Clinical Diagnostics Holdings plc Ordinary Shares
OCDX
| $62M | 1.2% | 3,324,000 +2,228,000 | +203% | +$41.6M |
|
21
Kraft Heinz
KHC
$33.1B
| $61.9M | 1.2% | 1,572,000 +208,000 | +15% | +$8.19M |
|
|
22
Vertex Pharmaceuticals
VRTX
$100B
| $61.6M | 1.19% | 236,000 -252,000 | -52% | -$65.8M |
|
|
23
Neurocrine Biosciences
NBIX
$13.8B
| $60.9M | 1.18% | +650,000 | New | +$60.9M |
|
24
AB InBev
BUD
$122B
| $58.7M | 1.14% | 978,000 +442,000 | +82% | +$26.5M |
|
25
Regeneron Pharmaceuticals
REGN
$61.5B
| $58.7M | 1.13% | 84,000 -32,000 | -28% | -$22.3M |
|